What Is Semaglutide Made From? Ingredients Explained

Semaglutide is a synthetic peptide built to mimic a natural human gut hormone called GLP-1, with three deliberate chemical modifications that keep it active in the bloodstream far longer than the hormone your body produces on its own. The drug’s “ingredients” span two layers: the active molecule itself, which is an engineered chain of amino acids with a fatty acid tail chemically bolted on, and the inactive ingredients in the finished product, which differ depending on whether you’re using an injectable pen or a swallowed tablet.

The Natural Hormone It Imitates

Your gut releases a hormone called GLP-1 (glucagon-like peptide-1) after you eat. GLP-1 tells the pancreas to release insulin, slows stomach emptying, and signals fullness to the brain. The problem with natural GLP-1 as a drug is that it falls apart almost immediately. Enzymes in the blood chew it up within about two minutes, making it useless as a medication you could take once a day, let alone once a week.

Semaglutide starts with the amino acid sequence of human GLP-1 and then alters it just enough to dodge those enzymes while still fitting into the same receptor. The modifications are precise: only a handful of positions in the 31-amino-acid chain are changed, and a fatty acid chain is attached to one specific spot. Every other amino acid in the molecule is identical to the one your own intestines produce.

Three Modifications That Make It a Drug

Two changes happen within the peptide backbone itself, and one is an entirely new chemical addition tethered to the chain.

The first backbone change is at position 8, where the natural amino acid alanine is swapped for a non-standard one called alpha-aminoisobutyric acid (Aib). This single swap is the main reason semaglutide resists being broken down by the enzyme DPP-4, which is the primary destroyer of natural GLP-1 in the bloodstream. Aib is bulkier than alanine and shields the nearby cleavage site from the enzyme’s active pocket.

The second backbone change is at position 34, where lysine is replaced with arginine. This substitution is less about enzymatic protection and more about controlling where the fatty acid side chain attaches. In the natural hormone, position 34 has a lysine that could attract unwanted chemical reactions during manufacturing. Swapping it to arginine ensures the fatty acid chain attaches only at the intended site: position 26.

The third modification is the most distinctive. A long fatty acid chain, specifically an 18-carbon fatty diacid, is connected through a chemical spacer (a short linker made of mini-PEG units and glutamic acid residues) to the lysine at position 26. This fatty tail is the reason semaglutide can be dosed once a week. It grabs onto albumin, the most abundant protein in blood plasma, and rides along with it. Since albumin circulates for weeks, semaglutide gets a free ride that extends its half-life to roughly a week. The fatty diacid also reduces how quickly the kidneys filter the drug out, which further slows its clearance.¹

How the Active Ingredient Is Manufactured

Making a 31-amino-acid peptide with a custom fatty acid tail is not simple. The pharmaceutical industry has traditionally relied on a process called solid-phase peptide synthesis (SPPS), where amino acids are added one by one to a growing chain that is anchored to a solid support bead. SPPS works, but it generates significant byproducts at each step, and the longer the peptide chain, the messier the process becomes. The accumulated impurities then require extensive purification to meet pharmaceutical-grade standards.

Newer approaches use genetically engineered bacteria, typically strains of E. coli, to produce the peptide backbone in bulk through fermentation. The bacteria are given a gene encoding a precursor version of semaglutide’s amino acid chain, and they churn out the precursor protein as they grow. This recombinant strategy has achieved yields that dwarf traditional chemical synthesis. One recent method produced the semaglutide main chain intermediate at over 5 grams per liter of fermentation broth, a substantial improvement over earlier approaches.²

After fermentation, the precursor has to be processed. In the recombinant approach, the bacteria produce a fusion protein: the semaglutide chain fused to a tag that helps with expression and solubility. That tag gets cleaved off using chemical or enzymatic methods, leaving the bare peptide chain ready for the next step. Compared to SPPS, recombinant production can skip some of the column-based purification steps that add cost and complexity, though the trade-off is that each method introduces its own set of downstream processing challenges.²

Regardless of whether the backbone is built chemically or biologically, the fatty acid side chain is attached afterward through a chemical conjugation step. The spacer and C18 fatty diacid are linked to the lysine at position 26 using standard organic chemistry reactions, and the final product is purified and analyzed for identity and purity before it goes anywhere near a patient.

Inactive Ingredients in the Injectable Formulations

If you use a semaglutide injection pen, the active peptide is dissolved in a sterile solution alongside several inactive ingredients that keep the drug stable, properly pH-balanced, and safe for repeated use. Typical components include a phosphate buffer to maintain pH, a preservative such as phenol to prevent microbial growth in multi-dose pens, and water for injection as the solvent. Small amounts of hydrochloric acid or sodium hydroxide may also be added to fine-tune the solution’s acidity.

None of these inactive ingredients are exotic. Phosphate buffers and phenol preservatives are standard across many injectable medications, from insulin to growth hormone. The semaglutide itself is present in very small quantities per dose, measured in milligrams, so the vast majority of what’s in the pen by volume is just buffered water.

What Makes the Oral Tablet Different

Oral semaglutide, sold as Rybelsus, faces a problem that injections sidestep entirely: surviving the stomach. Peptides are proteins, and your stomach is specifically designed to break proteins apart. Without help, semaglutide swallowed in a plain tablet would be digested before it ever reached the bloodstream.

The solution is a compound called SNAC, which stands for sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. SNAC is co-formulated with semaglutide in the tablet and acts as an absorption enhancer. When the tablet dissolves in the stomach, SNAC raises the local pH around the tablet, which inhibits the stomach enzyme pepsin from attacking the semaglutide molecules. SNAC also helps semaglutide pass through the stomach lining into the bloodstream by temporarily increasing the permeability of the gastric epithelium.³

SNAC does several things simultaneously: it elevates pH, encourages the semaglutide peptide to stay in its monomeric (single-molecule) form rather than clumping together, and directly inhibits pepsin activity in the immediate vicinity of the dissolving tablet.⁴ This is why the dosing instructions for oral semaglutide are so specific: you take it on an empty stomach with no more than a small sip of plain water, then wait at least 30 minutes before eating or drinking anything else. Food or a full glass of water would dilute the SNAC’s local effects and dramatically reduce absorption.

Beyond SNAC, the oral tablet contains standard pharmaceutical excipients: povidone (a binder that helps hold the tablet together), microcrystalline cellulose (a filler), and magnesium stearate (a lubricant used during the tablet-pressing process). Each 3 mg, 7 mg, or 14 mg tablet contains 300 mg of SNAC, meaning SNAC is actually the heaviest single component in the tablet by weight, far outweighing the milligram-scale amount of semaglutide itself.

Is Semaglutide Derived from Animals?

This comes up frequently, especially among vegetarians, vegans, and people with religious dietary considerations. The active molecule in semaglutide is entirely synthetic. Whether produced through chemical synthesis or bacterial fermentation, no animal tissues or animal-derived hormones are used in creating the peptide chain. The GLP-1 sequence that semaglutide is based on is a human hormone sequence, but the drug is not extracted from human intestines. It is built from scratch in a lab or bioreactor.

The fatty acid side chain is likewise synthetic. While C18 fatty acids exist naturally in animal and plant fats, the specific diacid and linker used in semaglutide are produced through industrial chemical processes, not by harvesting fat from animals.

One area that sometimes causes confusion is the use of E. coli bacteria in recombinant production. These are laboratory strains, heavily engineered and unrelated to disease-causing bacteria, used purely as microscopic factories. The bacterial material is completely removed during purification. The final drug product does not contain bacterial cells or bacterial proteins.

How Compounded Semaglutide Differs

During periods of high demand, some compounding pharmacies have produced their own versions of semaglutide. These compounded formulations have drawn scrutiny because they may not use the same salt form of the molecule as the FDA-approved products. Novo Nordisk, the manufacturer of Ozempic, Wegovy, and Rybelsus, uses a specific base form of semaglutide in its approved products. Some compounders have used semaglutide sodium salt or semaglutide acetate salt instead, which are chemically distinct even if the core peptide is the same.

Salt form matters because it can affect stability, potency, and how the drug behaves once injected. The inactive ingredients in compounded products also vary by pharmacy and are not subject to the same standardized manufacturing controls as FDA-approved formulations. This is one reason the FDA has issued warnings about compounded semaglutide: not because the core amino acid chain is necessarily different, but because the total formulation, including salt form, buffer, preservative, and sterility assurance, may not match the tested and approved product.

Quality Control and Purity

Peptide drugs are harder to purify than small-molecule pills because even minor impurities, like a peptide chain that’s one amino acid too short, or one where the fatty acid attached to the wrong lysine, can affect safety and effectiveness. Manufacturers use high-performance liquid chromatography (HPLC) and mass spectrometry to verify that each batch meets strict purity thresholds. Forced degradation studies, where the drug is deliberately exposed to heat, acid, and oxidative conditions, help identify what breakdown products might appear during storage so that the quality-control methods can detect them.

For recombinant production, purity benchmarks are especially critical because the starting material contains bacterial proteins that must be completely removed. Recent methods have achieved purities above 98% for the semaglutide intermediate chain after purification, before the fatty acid conjugation step.² The conjugation step and final purification then bring the complete molecule to pharmaceutical grade.

Why You Cannot Simply “Make” Semaglutide at Home

Given the growing interest in semaglutide and the existence of peptide synthesis services, some people wonder whether semaglutide could be obtained or assembled outside official pharmaceutical channels. Setting aside the legal issues, the practical barriers are steep. Even if you could acquire the correct amino acids, the Aib substitution, the arginine swap, and the fatty acid conjugation each require specialized reagents and reaction conditions. The conjugation chemistry alone demands controlled environments and analytical verification at each step.

More critically, the difference between a peptide that’s 95% pure and one that’s 99% pure can be the difference between a safe medication and one that causes immune reactions or has unpredictable potency. The analytical infrastructure needed to verify purity, equipment that typically costs hundreds of thousands of dollars, is as important as the synthesis itself. This is why even compounding pharmacies with professional equipment and trained staff have run into quality concerns with their semaglutide formulations.

The Role of the Linker

One ingredient that often gets overlooked in explanations of semaglutide is the chemical linker connecting the C18 fatty diacid to the peptide backbone. This linker is not just a passive connector. It’s a small chain made up of two mini-PEG (polyethylene glycol) units and two glutamic acid residues arranged in a specific geometry. The linker’s length and flexibility affect how freely the fatty acid tail can swing out and grab albumin in the bloodstream. Too short a linker and the tail is trapped against the peptide surface. Too long and the molecule becomes unstable or aggregation-prone.

The design of this linker is one of the features that distinguishes semaglutide from earlier GLP-1 receptor agonists. Liraglutide, an older drug in the same class, uses a shorter C16 fatty acid with a simpler glutamic acid linker and achieves a half-life of only about 13 hours, requiring daily injections. Semaglutide’s longer C18 fatty diacid on its more elaborate linker is a big part of why the drug lasts roughly a week. The linker ingredients themselves, mini-PEG and glutamic acid, are well-characterized pharmaceutical building blocks used across many drug conjugates.

Shelf Stability and Storage Ingredients

Peptide drugs are inherently fragile compared to small-molecule medications. The injectable formulation of semaglutide must be refrigerated before first use, though it can be kept at room temperature for a limited period once in use. The phosphate buffer and preservatives in the solution help slow chemical degradation, but even with those stabilizers, the peptide will eventually break down if exposed to heat or light for too long.

The oral tablet is more robust in some ways because it is a dry solid, and peptides in a dry state are less prone to the hydrolysis reactions that degrade them in solution. However, the SNAC component is sensitive to moisture, which is why Rybelsus tablets come individually sealed in foil blister packs rather than in a loose bottle. Patients are instructed not to split or crush the tablets, because the precise layering of SNAC around the semaglutide in the tablet matrix is designed to create the right concentration of absorption enhancer at the right moment as the tablet dissolves.

For anyone storing semaglutide at home, the practical takeaway is straightforward: follow the storage instructions printed on the packaging. The inactive ingredients in the formulation are chosen to maximize shelf life under those specific conditions. Deviating, like leaving an injection pen in a hot car or storing oral tablets outside their foil packaging, accelerates degradation of both the active peptide and the stabilizing excipients around it.